Skip to main content
Top
Published in: Archives of Virology 6/2017

01-06-2017 | Brief Report

Genotype analysis of ORF 62 identifies varicella-zoster virus infections caused by a vaccine strain in children

Authors: Byung Ok Kwak, Hoan Jong Lee, Hyun Mi Kang, Chi Eun Oh, Eun Hwa Choi

Published in: Archives of Virology | Issue 6/2017

Login to get access

Abstract

This study was performed to differentiate vaccine-type strains from wild-type strains and determine the genotype of varicella-zoster virus (VZV) in 51 Korean children. A sequencing analysis of ORF 62 identified two cases of herpes zoster caused by the vaccine-type virus, without a previous history of varicella, 22 months and 5 months after VZV vaccination. The wild-type strain was identified in the remaining children. A genotype analysis of ORF 22 amino acids revealed genotype J in all children except one. Genotype E was identified in an infant with varicella imported from Egypt.
Literature
1.
go back to reference Davison AJ, Scott JE (1986) The complete DNA sequence of varicella-zoster virus. J Gen Virol 67:1759–1816CrossRefPubMed Davison AJ, Scott JE (1986) The complete DNA sequence of varicella-zoster virus. J Gen Virol 67:1759–1816CrossRefPubMed
2.
go back to reference Schmidt-Chanasit J, Sauerbrei A (2011) Evolution and world-wide distribution of varicella-zoster virus clades. Infect Genet Evol 11:1–10CrossRefPubMed Schmidt-Chanasit J, Sauerbrei A (2011) Evolution and world-wide distribution of varicella-zoster virus clades. Infect Genet Evol 11:1–10CrossRefPubMed
3.
go back to reference Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 304:1288–1290CrossRef Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 304:1288–1290CrossRef
4.
go back to reference Nguyen HQ, Jumaan AO, Seward JF (2005) Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352:450–458CrossRefPubMed Nguyen HQ, Jumaan AO, Seward JF (2005) Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352:450–458CrossRefPubMed
5.
go back to reference Kim SH, Lee HJ, Park SE, Oh SH, Lee SY, Choi EH (2010) Seroprevalence rate after one dose of varicella vaccine in infants. J Infect 61:66–72CrossRefPubMed Kim SH, Lee HJ, Park SE, Oh SH, Lee SY, Choi EH (2010) Seroprevalence rate after one dose of varicella vaccine in infants. J Infect 61:66–72CrossRefPubMed
6.
go back to reference Galea SA, Sweet A, Beninger P, Steinberg SP, LaRussa PS, Gershon AA, Sharrar RG (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197:S165–S169CrossRefPubMed Galea SA, Sweet A, Beninger P, Steinberg SP, LaRussa PS, Gershon AA, Sharrar RG (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197:S165–S169CrossRefPubMed
7.
go back to reference Sauerbrei A, Eichhorn U, Gawellek S, Egerer R, Schacke M, Wutzler P (2003) Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain. J Med Virol 71:313–319CrossRefPubMed Sauerbrei A, Eichhorn U, Gawellek S, Egerer R, Schacke M, Wutzler P (2003) Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain. J Med Virol 71:313–319CrossRefPubMed
8.
go back to reference Sauerbrei A, Rubtcova E, Wutzler P, Schmid DS, Loparev VN (2004) Genetic profile of an Oka varicella vaccine virus variant isolated from an infant with zoster. J Clin Microbiol 42:5604–5608CrossRefPubMedPubMedCentral Sauerbrei A, Rubtcova E, Wutzler P, Schmid DS, Loparev VN (2004) Genetic profile of an Oka varicella vaccine virus variant isolated from an infant with zoster. J Clin Microbiol 42:5604–5608CrossRefPubMedPubMedCentral
9.
go back to reference LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg S, Silverstein S (1992) Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 66:1016–1020PubMedPubMedCentral LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg S, Silverstein S (1992) Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 66:1016–1020PubMedPubMedCentral
10.
go back to reference LaRussa P, Steinberg S, Arvin A, Dwyer D, Burgess M, Menegus M, Rekrut K, Yamanishi K, Gershon A (1998) Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. J Infect Dis 178:S64–S66CrossRefPubMed LaRussa P, Steinberg S, Arvin A, Dwyer D, Burgess M, Menegus M, Rekrut K, Yamanishi K, Gershon A (1998) Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. J Infect Dis 178:S64–S66CrossRefPubMed
11.
go back to reference Argaw T, Cohen JI, Klutch M, Lekstrom K, Yoshikawa T, Asano Y, Krause PR (2000) Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. J Infect Dis 181:1153–1157CrossRefPubMed Argaw T, Cohen JI, Klutch M, Lekstrom K, Yoshikawa T, Asano Y, Krause PR (2000) Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. J Infect Dis 181:1153–1157CrossRefPubMed
12.
go back to reference Loparev VN, Argaw T, Krause PR, Takayama M, Schmid DS (2000) Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J Clin Microbiol 38:3156–3160PubMedPubMedCentral Loparev VN, Argaw T, Krause PR, Takayama M, Schmid DS (2000) Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J Clin Microbiol 38:3156–3160PubMedPubMedCentral
13.
go back to reference Loparev VN, Gonzalez A, Deleon-Carnes M, Tipples G, Fickenscher H, Torfason EG, Schmid DS (2004) Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J Virol 78:8349–8358CrossRefPubMedPubMedCentral Loparev VN, Gonzalez A, Deleon-Carnes M, Tipples G, Fickenscher H, Torfason EG, Schmid DS (2004) Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J Virol 78:8349–8358CrossRefPubMedPubMedCentral
14.
go back to reference Loparev VN, Rubtcova E, Seward JF, Levin MJ, Schmid DS (2007) DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis 195:502–510CrossRefPubMed Loparev VN, Rubtcova E, Seward JF, Levin MJ, Schmid DS (2007) DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis 195:502–510CrossRefPubMed
15.
16.
go back to reference Bhalla P, Forrest GN, Gershon M, Zhou Y, Chen J, LaRussa P, Steinberg S, Gershon AA (2014) Disseminated persistent and fatal infection due to the vaccine strain (vOka) of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect 60:1068–1074 Bhalla P, Forrest GN, Gershon M, Zhou Y, Chen J, LaRussa P, Steinberg S, Gershon AA (2014) Disseminated persistent and fatal infection due to the vaccine strain (vOka) of varicella-zoster virus in an adult following stem cell transplantation. Clin Infect 60:1068–1074
17.
go back to reference Thomas SL, Hall AJ (2004) What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 4:26–33CrossRefPubMed Thomas SL, Hall AJ (2004) What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 4:26–33CrossRefPubMed
18.
go back to reference Adler AL, Casper C, Boeckh M, Heath J, Zerr DM (2008) An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients. Infect Control Hosp Epidemiol 29:866–870CrossRefPubMed Adler AL, Casper C, Boeckh M, Heath J, Zerr DM (2008) An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients. Infect Control Hosp Epidemiol 29:866–870CrossRefPubMed
19.
go back to reference Liang MG, Heidelberg KA, Jacobson RM, McEvoy MT (1998) Herpes zoster after varicella immunization. J Am Acad Dermatol 38:761–763CrossRefPubMed Liang MG, Heidelberg KA, Jacobson RM, McEvoy MT (1998) Herpes zoster after varicella immunization. J Am Acad Dermatol 38:761–763CrossRefPubMed
20.
go back to reference Uebe B, Sauerbrei A, Burdach S, Horneff G (2002) Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr 161:442–444CrossRefPubMed Uebe B, Sauerbrei A, Burdach S, Horneff G (2002) Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr 161:442–444CrossRefPubMed
21.
go back to reference Ota K, Kim V, Lavi S, Ford-Jones EL, Tipples G, Scolnik D, Tellier R (2008) Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old. Pediatr Infect Dis J 27:847–848CrossRefPubMed Ota K, Kim V, Lavi S, Ford-Jones EL, Tipples G, Scolnik D, Tellier R (2008) Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old. Pediatr Infect Dis J 27:847–848CrossRefPubMed
22.
go back to reference Gomi Y, Ozaki T, Nishimura N, Narita A, Suzuki M, Ahn J, Watanabe N, Koyama N, Ushida H, Yasuda N, Nakane K, Funahashi K, Fuke I, Takamizawa A, Ishikawa T, Yamanishi K, Takahashi M (2008) DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine. Vaccine 26:5627–5632CrossRefPubMed Gomi Y, Ozaki T, Nishimura N, Narita A, Suzuki M, Ahn J, Watanabe N, Koyama N, Ushida H, Yasuda N, Nakane K, Funahashi K, Fuke I, Takamizawa A, Ishikawa T, Yamanishi K, Takahashi M (2008) DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine. Vaccine 26:5627–5632CrossRefPubMed
23.
go back to reference Iyer S, Mittal MK, Hodinka RL (2009) Herpes zoster and meningitis resulting from reactivation of varicella vaccine virus in an immunocompetent child. Ann Emerg Med 53:792–795CrossRefPubMed Iyer S, Mittal MK, Hodinka RL (2009) Herpes zoster and meningitis resulting from reactivation of varicella vaccine virus in an immunocompetent child. Ann Emerg Med 53:792–795CrossRefPubMed
24.
go back to reference Chouliaras G, Spoulou V, Quinlivan M, Breuer J, Theodoridou M (2010) Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child. Pediatrics 125:e969–e972CrossRefPubMed Chouliaras G, Spoulou V, Quinlivan M, Breuer J, Theodoridou M (2010) Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child. Pediatrics 125:e969–e972CrossRefPubMed
25.
go back to reference Han JY, Hanson DC, Way SS (2011) Herpes zoster and meningitis due to reactivation of varicella vaccine virus in an immunocompetent child. Pediatr Infect Dis J 30:266–268CrossRefPubMed Han JY, Hanson DC, Way SS (2011) Herpes zoster and meningitis due to reactivation of varicella vaccine virus in an immunocompetent child. Pediatr Infect Dis J 30:266–268CrossRefPubMed
26.
go back to reference Chaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, Seward JF (2008) Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995–2005. J Infect Dis 197:S170–S177CrossRefPubMed Chaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, Seward JF (2008) Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995–2005. J Infect Dis 197:S170–S177CrossRefPubMed
27.
go back to reference Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA (2008) Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis 197:S196–S199CrossRefPubMed Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA (2008) Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis 197:S196–S199CrossRefPubMed
28.
go back to reference Sauerbrei A, Zell R, Harder M, Wutzler P (2006) Genotyping of different varicella vaccine strains. J Clin Virol 37:109–117CrossRefPubMed Sauerbrei A, Zell R, Harder M, Wutzler P (2006) Genotyping of different varicella vaccine strains. J Clin Virol 37:109–117CrossRefPubMed
29.
go back to reference Loparev VN, Rubtcova EN, Bostik V, Govil D, Birch CJ, Druce JD, Schmid DS, Croxson MC (2007) Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J Virol 81:12758–12765CrossRefPubMedPubMedCentral Loparev VN, Rubtcova EN, Bostik V, Govil D, Birch CJ, Druce JD, Schmid DS, Croxson MC (2007) Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J Virol 81:12758–12765CrossRefPubMedPubMedCentral
30.
go back to reference Breuer J, Grose C, Norberg P, Tipples G, Schmid DS (2010) A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24–25 July 2008. J Gen Virol 91:821–828CrossRefPubMedPubMedCentral Breuer J, Grose C, Norberg P, Tipples G, Schmid DS (2010) A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24–25 July 2008. J Gen Virol 91:821–828CrossRefPubMedPubMedCentral
31.
32.
go back to reference Marshall HS, McIntyre P, Richmond P, Buttery JP, Royle JA, Gold MS, Wood N, Elliott EJ, Zurynski Y, Toi CS (2013) Changes in patterns of hospitalized children with varicella and of associated varicella genotypes after introduction of varicella vaccine in Australia. Pediatr Infect Dis J 32:530–537CrossRefPubMed Marshall HS, McIntyre P, Richmond P, Buttery JP, Royle JA, Gold MS, Wood N, Elliott EJ, Zurynski Y, Toi CS (2013) Changes in patterns of hospitalized children with varicella and of associated varicella genotypes after introduction of varicella vaccine in Australia. Pediatr Infect Dis J 32:530–537CrossRefPubMed
33.
go back to reference Choi YJ, Kim KH, Oh MD (2010) Genotype of varicella zoster virus isolated from Korean elderly patients with herpes zoster. Infect Chemother 42:162–170CrossRef Choi YJ, Kim KH, Oh MD (2010) Genotype of varicella zoster virus isolated from Korean elderly patients with herpes zoster. Infect Chemother 42:162–170CrossRef
34.
go back to reference Kim KH, Choi YJ, Song KH, Park WB, Jeon JH, Park SW, Kim HB, Kim NJ, Oh MD (2011) Genotype of varicella-zoster virus isolates in South Korea. J Clin Microbiol 49:1913–1916CrossRefPubMedPubMedCentral Kim KH, Choi YJ, Song KH, Park WB, Jeon JH, Park SW, Kim HB, Kim NJ, Oh MD (2011) Genotype of varicella-zoster virus isolates in South Korea. J Clin Microbiol 49:1913–1916CrossRefPubMedPubMedCentral
Metadata
Title
Genotype analysis of ORF 62 identifies varicella-zoster virus infections caused by a vaccine strain in children
Authors
Byung Ok Kwak
Hoan Jong Lee
Hyun Mi Kang
Chi Eun Oh
Eun Hwa Choi
Publication date
01-06-2017
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 6/2017
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-017-3276-6

Other articles of this Issue 6/2017

Archives of Virology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine